• 1. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 5. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Pyrimidinecarboxylic acids and derivatives

2-Ethyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid: A Promising Compound in Pharmaceutical Research

2-Ethyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid (CAS No. 1267654-20-5) represents a significant advancement in the field of pharmaceutical chemistry. This compound, characterized by its unique molecular structure, has garnered attention for its potential applications in drug discovery and therapeutic development. The 2-Ethyl group and the 6-oxo functionalization within the 1,6-dihydropyrimidine ring system are critical features that influence its biological activity and chemical reactivity. The 4-carboxylic acid moiety further enhances its interaction with biological targets, making it a versatile scaffold for medicinal chemistry.

Recent studies have highlighted the importance of 2-Ethyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid in modulating key signaling pathways. For instance, a 2023 publication in Journal of Medicinal Chemistry demonstrated its ability to inhibit the phosphorylation of ERK1/2 (extracellular signal-regulated kinase 1/2), a critical pathway in cell proliferation and survival. This finding suggests potential applications in oncology, where targeting aberrant signaling cascades is a priority. The compound's 4-carboxylic acid group may contribute to its interaction with serine/threonine kinases, enhancing its efficacy in modulating these pathways.

Structural analysis of 2-Ethyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid reveals its compatibility with various synthetic methodologies. A 2024 study in Organic & Biomolecular Chemistry reported the development of a scalable approach to synthesize this compound using microwave-assisted catalytic methods. This technique significantly reduces reaction times and energy consumption, aligning with the growing emphasis on green chemistry in pharmaceutical manufacturing. The 1,6-dihydropyrimidine core structure is particularly amenable to functionalization, allowing for the incorporation of diverse pharmacophores that can be tailored for specific therapeutic applications.

Pharmacological investigations into 2-Ethyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid have revealed its potential as an anti-inflammatory agent. A 2023 preclinical study published in Pharmacological Research demonstrated its ability to suppress the production of pro-inflammatory cytokines such as IL-6 and TNF-α in LPS-stimulated macrophages. This effect is attributed to the compound's ability to modulate the NF-κB signaling pathway, a central regulator of inflammatory responses. The 4-carboxylic acid group may play a role in stabilizing the interaction between the compound and key proteins involved in this pathway.

Advances in computational modeling have further elucidated the binding mechanisms of 2-Ethyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid. A 2024 study using molecular docking simulations revealed its high affinity for the VEGFR-2 (vascular endothelial growth factor receptor 2) kinase domain, a target implicated in angiogenesis and tumor progression. This finding suggests potential applications in anti-angiogenic therapies for cancer treatment. The 6-oxo functionalization may enhance the compound's ability to form hydrogen bonds with critical residues in the kinase active site, improving its inhibitory potency.

Research into the 1,6-dihydropyrimidine scaffold has also explored its potential in neurodegenerative disease therapies. A 2023 study in Neuropharmacology investigated the effects of 2-Ethyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid on the aggregation of β-amyloid peptides, a hallmark of Alzheimer's disease. The compound was found to disrupt fibril formation and reduce toxicity in neuronal cell models, suggesting its potential as a therapeutic agent for neurodegenerative disorders. The 4-carboxylic acid group may contribute to its interaction with amyloidogenic proteins, enhancing its ability to modulate pathological processes.

Optimization of 2-Ethyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid has led to the development of analogs with improved pharmacokinetic profiles. A 2024 study in Drug Discovery Today reported the synthesis of several derivatives with enhanced oral bioavailability and reduced metabolic instability. These modifications, which involve the introduction of hydrophobic substituents on the 2-Ethyl group, demonstrate the importance of structure-activity relationship (SAR) studies in drug design. The 4-carboxylic acid moiety remains a key functional group, as it maintains the compound's ability to interact with target proteins while improving its metabolic stability.

Future research on 2-Ethyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid is likely to focus on its potential in combination therapies. Given its ability to modulate multiple signaling pathways, this compound may serve as a lead molecule for the development of multi-target drugs. A 2023 review in Current Pharmaceutical Design highlighted the advantages of multi-target approaches in treating complex diseases such as cancer and diabetes. The 1,6-dihydropyrimidine scaffold provides a flexible platform for the incorporation of additional pharmacophores, enabling the design of compounds with broader therapeutic applications.

As the field of medicinal chemistry continues to evolve, 2-Ethyl-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid stands as a promising candidate for further exploration. Its unique molecular structure and diverse biological activities position it as a valuable scaffold for the development of novel therapeutics. Ongoing research into its mechanisms of action and potential applications will undoubtedly contribute to advancements in pharmaceutical science and the treatment of various diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)